» Articles » PMID: 37633277

Mechanism-based Inhibition of Gut Microbial Tryptophanases Reduces Serum Indoxyl Sulfate

Overview
Journal Cell Chem Biol
Publisher Cell Press
Specialty Biochemistry
Date 2023 Aug 26
PMID 37633277
Authors
Affiliations
Soon will be listed here.
Abstract

Indoxyl sulfate is a microbially derived uremic toxin that accumulates in late-stage chronic kidney disease and contributes to both renal and cardiovascular toxicity. Indoxyl sulfate is generated by the metabolism of indole, a compound created solely by gut microbial tryptophanases. Here, we characterize the landscape of tryptophanase enzymes in the human gut microbiome and find remarkable structural and functional similarities across diverse taxa. We leverage this homology through a medicinal chemistry campaign to create a potent pan-inhibitor, (3S) ALG-05, and validate its action as a transition-state analog. (3S) ALG-05 successfully reduces indole production in microbial culture and displays minimal toxicity against microbial and mammalian cells. Mice treated with (3S) ALG-05 show reduced cecal indole and serum indoxyl sulfate levels with minimal changes in other tryptophan-metabolizing pathways. These studies present a non-bactericidal pan-inhibitor of gut microbial tryptophanases with potential promise for reducing indoxyl sulfate in chronic kidney disease.

Citing Articles

A Circular Network of Coregulated L-Threonine and L-Tryptophan Metabolism Dictates Acute Lower Limb Ischemic Injury.

Li L, Xiao C, Liu H, Chen S, Tang Y, Zhou H Int J Med Sci. 2024; 21(12):2402-2413.

PMID: 39310266 PMC: 11413896. DOI: 10.7150/ijms.102177.


The gut microbiota in thrombosis.

Khuu M, Paeslack N, Dremova O, Benakis C, Kiouptsi K, Reinhardt C Nat Rev Cardiol. 2024; 22(2):121-137.

PMID: 39289543 DOI: 10.1038/s41569-024-01070-6.


Structural Snapshots of Tryptophan Indole-Lyase Reveal Insights into the Catalytic Mechanism.

Phillips R, Brown S, Patel R ACS Catal. 2024; 14(15):11498-11511.

PMID: 39114092 PMC: 11301627. DOI: 10.1021/acscatal.4c03232.

References
1.
Zakharia Y, McWilliams R, Rixe O, Drabick J, Shaheen M, Grossmann K . Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma. J Immunother Cancer. 2021; 9(6). PMC: 8202104. DOI: 10.1136/jitc-2020-002057. View

2.
Fattah H, Layton A, Vallon V . How Do Kidneys Adapt to a Deficit or Loss in Nephron Number?. Physiology (Bethesda). 2019; 34(3):189-197. PMC: 6734068. DOI: 10.1152/physiol.00052.2018. View

3.
Devlin A, Marcobal A, Dodd D, Nayfach S, Plummer N, Meyer T . Modulation of a Circulating Uremic Solute via Rational Genetic Manipulation of the Gut Microbiota. Cell Host Microbe. 2016; 20(6):709-715. PMC: 5159218. DOI: 10.1016/j.chom.2016.10.021. View

4.
Pettersen E, Goddard T, Huang C, Meng E, Couch G, Croll T . UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 2020; 30(1):70-82. PMC: 7737788. DOI: 10.1002/pro.3943. View

5.
Benech N, Rolhion N, Sokol H . Tryptophan metabolites get the gut moving. Cell Host Microbe. 2021; 29(2):145-147. DOI: 10.1016/j.chom.2021.01.009. View